Albert & Jakobiec's Principles & Practice of Ophthalmology, 3rd Edition

CHAPTER 154 - Pathologic Myopia

Adrienne W. Scott,
Sharon Fekrat

Overview

Pathologic, or degenerative myopia, has been defined as refractive error more negative than ?6 D, and is a leading cause of blindness in Asian countries. It is a multifactorial disorder with genetic, environmental, and socioeconomic etiologies. The pathogenesis of pathologic myopia is not known. Defective collagen fibril formation results in biomechanically weak sclera and progressive globe elongation. Numerous complications, such as posterior vitreous detachment (PVD) and abnormal vitreoretinal interface, retinal detachment (RD), posterior staphyloma, macular hole, lacquer cracks (spontaneous breaks in Bruch's membrane), subretinal hemorrhage, lead to visual disability. The most common visually threatening complication of pathologic myopia is choroidal neovascularization (CNV).

Myopia-related CNV lesions are usually self-limited, and are smaller and less exudative than CNV observed in age-related macular degeneration (AMD). Argon laser has been used to treat extrafoveal CNV with a high rate of posttreatment recurrence. Photodynamic therapy (PDT) has been established as a treatment to preserve visual acuity for subfoveal myopic CNV. Antiangiogenic therapy is a promising treatment option. Surgical treatments to displace the myopic CNV have also been utilized in attempts to salvage remaining visual acuity in these eyes.

Anticholinergic therapy is being studied as a way to slow myopic degeneration. As yet, there is no proven method to prevent the axial elongation and the myriad resulting posterior segment complications described in pathologic myopia.

INTRODUCTION

Myopia, or nearsightedness, is the most common ocular condition. Myopia occurs when an object image is formed anterior to the retinal surface, due to an excessively steep corneal curvature, an abnormally spherical lens, an increase in lenticular index of refraction as in nuclear sclerosis, or more commonly, as a result of increased axial length.[1]

Pathologic, myopia occurs when progressive increase in axial length causes excessive thinning of the sclera, retina, retinal pigment epithelium (RPE) and choroid, resulting in varying degrees of visual disability. Pathologic myopia has been assigned varying definitions in the ophthalmic literature. Duke-Elder defined pathologic myopia as myopia accompanied by degenerative posterior segment changes.[2,3] Pathologic myopia has also been defined as high myopia accompanied by visual dysfunction.[3,4] The American Academy of Ophthalmology Basic Clinical Science Course defines pathologic myopia as refractive error greater than ?6 D, with axial length in excess of 26.5 mm.[5]

 

 

PREVALENCE

Myopia is the most common refractive error and affects ~25% of adults in the United States.[6] Various demographic characteristics have been shown to be associated with high myopia. Female gender, younger age, earlier onset of myopia, and family history are all risk factors found to be associated with an increased likelihood of progressive myopia. Increased income and educational level have been associated with high levels of myopia, likely due to their correlation with increased levels of near work.[6]

Myopia prevalence varies among racial demographics. One study estimated prevalence of myopia in African-Americans in the United States at 13%.[7] Recently, the Los Angeles Latino Eye Study estimated an overall prevalence of myopia in adult Latinos in one community at 16.8%, with estimated prevalence of high myopia in this community at 2.4%.[8] A very high prevalence of myopia has been reported among Asians. Fredrick reported the overall prevalence of myopia to be as high as 70-90% in Asian populations.[9] While 0.2-0.4% of the US population was found to have refractive error greater than ?7.9 D,[7] the prevalence of pathologic myopia in Asian countries has been reported to be as high as 1%.[4]

 

 

PATHOGENESIS

It is well accepted that pathologic myopia is characterized by progressive scleral thinning with localized ectasia. The exact pathogenesis of pathologic myopia, however, is not entirely understood. It is postulated that myopic sclera is biomechanically weak and has been demonstrated to alter its composition and rigidity in response to environmental and visual stimuli. Remodeling of extracellular matrix by matrix metalloproteinases and their tissue inhibitors leads to abnormalities in collagen fiber bundles and a reduction in the size of individual collagen fibers in myopic eyes.[10] Myopia has been induced in animal models by defocusing the retinal image, triggering a cascade of events that leads to axial elongation.[11] Cholinergic pathways have been studied as mediators of scleral elongation associated with myopia. Other neurotransmitters such as dopamine, vasoactive intestinal peptide, and glucagon have also been implicated as possible mediators of scleral growth.[12]

 

 

ASSOCIATIONS

A variety of ocular morbidities such as low-tension glaucoma, amblyopia, strabismus, early cataract formation, image minification, decreased contrast sensitivity, and visual field defects have all been associated to occur in association with pathologic myopia. Stickler syndrome, Wagner syndrome, Ehlers-Danlos syndrome, and Marfan's syndrome are hereditary conditions that have been associated with axial high myopia.

 

 

COMPLICATIONS

The fundus changes observed in conjunction with pathologic myopia most notably lead to visual deterioration and blindness in highly myopic individuals. A trademark of the myopic posterior segment clinical examination is the tessellated, or tigroid fundus, in which choroidal vessels are evident below the thinned, atrophic retina and RPE (Fig. 154.1). This and other abnormal posterior segment findings in pathologic myopia were described in a large, retrospective, histopathologic examination of enucleated eyes with degenerative myopia by Grossniklaus and Green.[13] Myopic configuration of the optic nerve head was the most frequently associated finding, present in 37.7% of eyes. Posterior staphyloma and vitreous degeneration were the next most frequently observed findings.[13]

Click to view full size figure  

 

FIGURE 154.1  Typical fundus appearance of pathologic myopia. This patient has 20/60 vision with ?20 D correction. Note tilted optic nerve with peripapillary crescent, tigroid fundus appearance, attenuated vessels, and chorioretinal atrophy.
Photo courtesy of Srilaxmi Bearelly, MD.

 

 

Pathologic myopic retinopathy is particularly visually devastating, as it is irreversible, often bilateral, and affects individuals at younger ages during their productive years.[14] The major visually threatening complications of myopic retinopathy are discussed below.

 

 

POSTERIOR VITREOUS DETACHMENT

Highly myopic eyes are characterized by premature posterior vitreous detachment (PVD). The incidence of PVD in highly myopic patients has been strongly correlated with increased axial length, age, and degree of myopia compared to controls.[15] A PVD is often preceded by vitreous syneresis, and the formation of fluid pockets within the vitreous gel.[1] Acute PVD may produce photopsia and a symptomatic 'floater', in which shadows are cast on the retinal surface as a result of vitreous condensation and opacification. Detachment of the posterior vitreous may also cause acute vitreous hemorrhage if retinal vessels are avulsed at the time of posterior vitreous separation. A PVD may cause retinal traction and lead to a retinal break as well as the most common surgical complication of high myopia-rhegmatogenous retinal detachment (RRD).

 

 

RETINAL DETACHMENT

A break in the retina causes liquified vitreous fluid to travel underneath the retina into the subretinal space, detaching the retina. RRD may result from a retinal tear, retinal dialysis, macular hole, or as a result of acute PVD as described previously. In the general population, the retinal detachment incidence is less than 1%, RRD occurs more frequently in eyes with increased axial length.[3] This increased likelihood of RRD in high myopes is due to peripheral retinal abnormalities such as lattice degeneration, increased frequency of PVD, and an abnormal vitreoretinal interface caused by increased axial length.

RRD as a result of macular hole formation is more likely to occur in eyes with pathologic myopia (Fig. 154.2). One study reported 6.3% of highly myopic eyes to develop an asymptomatic macular hole, confirmed by ocular coherence tomography (OCT).[16]

Click to view full size figure  

 

FIGURE 154.2  RD resulting from a macular hole (black arrow) in a patient with pathologic myopia.
Photo courtesy of Brooks W. McCuen, MD.

 

 

High myopia also predisposes eyes to RRD after cataract surgery. Highly myopic eyes undergoing cataract surgery are more likely to develop a postoperative retinal detachment when compared to controls.[17] Pars plana vitrectomy (PPV) with or without scleral buckling, with or without gas or silicone oil tamponade may be used to repair RRD.

 

 

OPTIC NERVE

Globe elongation leads to characteristic optic nerve changes. The tilted optic nerve is often seen in eyes with pathologic myopia. Thinning of the retina and RPE leads to the peripapillary temporal crescent observed to surround the optic nerve head (Fig. 154.1). A recently described optic nerve finding is peripapillary detachment. Freund and colleagues reported peripapillary detachment as an elevated, yellow-orange lesion inferior to the optic disk seen in highly myopic eyes.[18] OCT demonstrated a localized retinal pigment epithelial detachment corresponding to the lesion. Peripapillary detachment was not observed to be visually significant. In another study, peripapillary detachment was present in as many as 4.9% of highly myopic eyes and was associated with glaucomatous optic nerve defects in 71% of eyes.[19]

 

 

POSTERIOR STAPHYLOMA

Localized, progressive globe elongation and resulting scleral ectasia leads to the development of a posterior staphyloma, another hallmark of degenerative myopia (Fig. 154.3). The prevalence of staphyloma formation correlates with axial length. Posterior staphyloma may cause visual field deficits, and central visual acuity may be affected if the staphyloma involves the macula. Increased likelihood of retinal detachment and formation of macular hole have been associated with posterior staphyloma formation in a study by Oie and colleagues.[20]

Click to view full size figure  

 

FIGURE 154.3  OCT in a patient with pathologic myopia. Visual acuity is 20/200 with a spherical equivalent of ?22 D. Note the posterior staphyloma, and the hyperreflectivity of the tissues underlying the atrophic retina. A partial PVD overlies the macula.
Photo courtesy of James Kesler, MD, FACS.

 

 

 

 

LACQUER CRACKS

Excessive tissue stress in pathologic myopia may also result in lacquer crack formation - focal, linear breaks in Bruch's membrane. Lacquer cracks may cause spontaneous subretinal hemorrhage (Fig. 154.4) at the time of formation, and may produce symptoms of acute photopsia, metamorphopsia, or scotoma.[1] A later complication of lacquer crack formation is the development of secondary CNV.

Click to view full size figure  

 

FIGURE 154.4  Subretinal hemorrhage in a myopic eye. This ?11.5 D myopic patient experienced a decrease in vision to 20/80 from submacular hemorrhage.
Photo courtesy of Srilaxmi Bearelly, MD.

 

 

 

 

MYOPIC CNV

Macular CNV occurs in 5-10% of eyes that are highly myopic[21,22] and is the most common visually threatening complication of pathologic myopia.[3,23-25] In its later stages, CNV due to pathologic myopia may be called a Fuchs spot. Foerster also described hemorrhagic lesions in myopic eyes which may describe a different stage in myopic CNV formation.[26,27] It has been observed that CNV in persons younger than 50 is seen most often in conjunction with pathologic myopia.[28]

 

 

NATURAL HISTORY OF MYOPIC CNV

The natural history of myopic CNV is variable. Yoshida and colleagues reported a generally poor prognosis for these untreated eyes with vision decreasing to worse than 20/200 at 10-year follow-up.[29] The same group also reported favorable characteristics of highly myopic eyes with CNV, which include younger age at onset, smaller CNV lesion size, and juxtafoveal location. Degree of myopia did not appear to influence prognosis in this study.[30] Myopic CNV appears to be a self-limited process with low activity and rapid absorption. It is, however, the development of chorioretinal atrophy around the myopic CNV that has been observed to enlarge, involve the fovea in some cases, and cause a further decrease in visual acuity.[24,31]

 

 

MEDICAL TREATMENTS OF MYOPIC CNV

Treatment modalities aimed toward treating CNV related to age-related macular degeneration (AMD) have been applied to the treatment of CNV in myopic eyes. CNV does, however, differ between these two groups in that most CNV lesions in association with pathologic myopia are classic, less exudative, and smaller as compared to CNV lesions in AMD.[3] Laser photocoagulation was the primary available treatment option for myopia-associated CNV prior to the 1990s.[3,19,32-36] Laser photocoagulation has shown short-term efficacy in limiting the extension of the extrafoveal or juxtafoveal CNV. A long-term study comparing the natural history of myopic CNV with laser treatment found that the visual acuity was preserved only after the first 2 years of follow-up.[30] At 5-year follow-up, there was no significant difference in visual acuity between treated and untreated eyes. The CNV is subject to recur along the border of the laser scar in treated eyes, with recurrence rates reported as high as 31-72%.[3,26-30,32-35] In addition to the immediate scotoma formation caused by laser treatment, further loss of central visual acuity may result in laser-treated myopic eyes with laser scar expansion, a process known as 'atrophic creep'.[3]

Photodynamic therapy (PDT) with verteporfin has been a major treatment option in eyes with myopia-related subfoveal CNV. PDT involves the administration of an intravenous photosensitive verteporfin dye which selectively accumulates in the CNV lesion.[3] Diode laser is then used to activate the accumulated dye and cause occlusion of the choroidal neovascular vessels. Two-year data from the Verteporfin in Photodynamic (VIP) Therapy Study Group showed maintained visual benefit of the PDT-treated group as compared to the placebo therapy group at 2-year follow-up.[37] Other studies have corroborated the VIP data, observing that PDT can increase the chance of visual stabilization or improvement compared with placebo.[38] Intravitreal corticosteroids are also being considered in myopic CNV therapy in conjunction with PDT.[39] Though PDT has been shown to have a treatment benefit in highly myopic CNV lesions, as with thermal laser treatment, the potential exists for posttreatment RPE damage, and posttreatment laser expansion of chorioretinal atrophy in the myopic eye after PDT treatment.[3]

Angiogenic growth factors such as vascular endothelial growth factor (VEGF) are implicated in the pathogenesis of ocular neovascularization in the human eye.[40,41] As in the case of neovascular AMD, VEGF inhibition is being studied as a treatment modality in myopia-related CNV.[42] Clinical trials are currently underway to evaluate anti-VEGF therapy in pathologic myopia.

 

 

SURGICAL TREATMENTS FOR MYOPIC CNV

Surgical removal of CNV in pathologic myopia has been performed.[43,44] No significant improvement in visual acuity has been reported, and surgical extraction of myopic CNV has been associated with high recurrence rates and postsurgical RPE atrophy.[3,43-46]

Another surgical intervention, macular translocation, is a complex surgical procedure first described as a treatment for macular degeneration by Machemer and Steinhorst.[3,46] Macular translocation involves moving the overlying sensory retina from the subfoveal CNV bed to a new location overlying healthy RPE.[3]

Proliferative vitreoretinopathy has been a frequent postoperative complication.[3] Further study is needed to establish the role of macular translocation in the treatment of myopic CNV.

 

 

TREATMENT

The treatments mentioned previously are all dedicated to mitigating the visual disability due to complications of pathologic myopia. There is no known cure for the globe elongation responsible for the complications experienced by those with pathologic myopia. Prevention of myopic degeneration has been attempted with anticholinergic agents, such as atropine[47,48] and pirenzipine,[49] that have been studied as possible therapeutic agents to slow scleral growth in humans.

Scleral reinforcement surgery has been attempted to arrest the axial globe elongation which occurs in pathologic myopia.[1,50] The clinical benefit of these procedures has as yet been unproven in a randomized, controlled clinical trial.

Refractive surgery procedures, such as laser in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), and radial keratotomy (RK), have achieved emmetropia in high myopes through alterations of corneal architecture. Phakic refractive lenses and cataract surgery have also been utilized to minimize myopic refractive error. These procedures, however, do not eliminate the myriad posterior segment complications that threaten the visual acuity of high myopes.

High myopia is a multifactorial disorder, with environmental, socioeconomic, and genetic factors playing a role in myopic degeneration. An X-linked form of pathologic myopia has been described,[51] and Young and associates have identified a chromosomal locus for autosomal dominant high myopia.[52] Discovery of other genes involved in high myopia may make gene therapy a potential area for future treatment.

Key Features

  

.   

Tigroid, or blond fundus, with choroidal vessels visible underneath

  

.   

Tilted optic nerve with peripapillary atrophy

  

.   

Peripapillary detachment

  

.   

Chorioretinal atrophy

  

.   

Posterior vitreous detachment

  

.   

Retinal detachment

  

.   

Lacquer cracks

  

.   

Lattice degeneration (spontaneous breaks in Bruch's membrane)

  

.   

Cobblestone degeneration

  

.   

Fuchs' spot (RPE hyperplasia in response to CNV)

  

.   

Scleral thinning

  

.   

Peripheral retinal holes

  

.   

Macular holes causing retinal detachment

  

.   

Choroidal neovascularization

 

Treatment Options for Myopic CNV

  

.   

Observation

  

.   

Photodynamic therapy with or without intravitreal steroid injection (FDA approved for subfoveal CNV)

  

.   

Argon laser (used for extrafoveal CNV, high rate of CNV recurrence and expansion of RPE scarring after treatment)

  

.   

Transpupillary thermotherapy

  

.   

Angiogenesis inhibition

  

.   

Surgical extraction of CNV lesion

  

.   

Macular translocation

 

 

REFERENCES

1. Pruett RC: Pathologic myopia.  Albert and Jakobiec's principles and practice of ophthalmology,  2nd edn. Philadelphia, PA: WB. Saunders Ca; 2000:878-882.

2. Duke-Elder S: Pathologic refractive errors. System of ophthalmology. vol V. Ophthalmic optics and refraction,  Louis: Mosby; 1970:297-373.

3. Tano Y: LIX Edward Jackson Memorial Lecture. Pathologic myopia: where are we now.  Am J Ophthalmol  2002; 134:645-660.

4. Tokoro T: On the de-nition of pathologic myopia in group studies.  Acta Ophthalmol  1988; 66:107-108.

5. American Academy of Ophthalmology : Pathologic myopia.  Retina and vitreous, basic and clinical science course. 2003,  San Francisco: American Academy of Ophthalmology; 2003:74.

6. Eye Disease Prevalence Research Group : The prevalence of refractive errors among adults in the United States, Western Europe, and Australia.  Arch Ophthalmol  2004; 122:495-505.

7. Sperduto RD, Seigel D, Roberts J, Rowland M: Prevalence of myopia in the United States.  Arch Ophthalmol  1983; 101:405-407.

8. Tarczy-Hornoch K, Ying-Lai M, Varma R, et al: Myopic refractive error in adult Latinos: the Los Angeles Latino Eye Study.  IOVS  2006; 47:1845-1852.

9. Fredrick DR: Myopia.  BMJ  2002; 324:1195-1199.

10. Rada JA, Shelton S, Norton TT: The sclera and myopia.  Exp Eye Res  2006; 82:185-200.

11. Wallman J: Retinal control of eye growth and refraction.  Prog Ret Res  1993; 12:133-153.

12. Crewther DP: The role of photoreceptors in the control of refractive state.  Prog Retina Eye Res  2000; 19:421-457.

13. Grossniklaus HE, Green WR: Pathologic findings in pathologic myopia.  Retina  1992; 12:127-133.

14. Shih YF, Ho TC, Hsiao CK, et al: Visual outcomes for high myopic patients with or without myopic maculopathy: a 10-year follow up study.  Br J Ophthalmol  2006; 90:546-550.

15. Ye J, Zhou C, Du H, et al: Study on the posterior vitreous detachment in patients with high myopia.  Zhongguo Yi Xue Ke Xue Yuan Xue Bao  1999; 21:472-477.

16. Coppe AM, Ripandelli G, Parisi V, et al: Prevalence of asymptomatic macular holes in highly myopic eyes.  Ophthalmol  2005; 112:2103-2109.

17. Ripandelli G, Scassa C, Parisi V, et al: Cataract surgery as a risk factor for retinal detachment in very highly myopic eyes.  Ophthalmology  2003; 110:2355-2361.

18. Freund KB, Ciardella AP, Yannuzzi LA, et al: Peripapillary detachment in pathologic myopia.  Arch Ophthalmol  2003; 121:197-204.

19. Shimada N, Ohno-Matsui K, Yoshida T, et al: Characteristics of peripapillary detachment in peripapillary myopia.  Arch Ophthalmol  2006; 124:46-52.

20. Oie Y, Ikuno Y, Fujikado T, Tano Y: Relation of posterior staphyloma in highly myopic eyes with macular hole and retinal detachment.  Jpn J Ophthalmol  2005; 49:530-532.

21. Curtin BJ: Basic science and clinical management.   In: Curtin BJ, ed. The myopias,  Philadelphia: Harper & Row; 1985:237-245.

22. Grossniklaus HE, Green WR: Pathologic findings in pathologic myopia.  Retina  1992; 12:127-133.

23. Avila MP, Weiter JJ, Jalkh AE, et al: Natural history of choroidal neovascularization in degenerative myopia.  Ophthalmology  1984; 91:1573-1581.

24. Fried M, Siebert A, Meyer-Schwickerath G: A natural history of Fuchs' spot. A long term follow-up study.  Doc Ophthalmol  1981; 28:215-221.

25. Hampton GR, Kohen D, Bird AC: Visual prognosis of disciform degeneration in myopia.  Ophthalmology  1983; 90:923-926.

26. Foerster R: Ophthalmologische beitrage,  Berlin: Enslin; 1862:55.

27. Soubrane G, Coscas G: Choroidal neovascular membrane in degenerative myopia.   In: Schachat AP, Murphy RP, Ryan SJ, ed. Retina,  Los Angeles: Mosby; 1994:1149.

28. Cohen SY, Laroche A, Leguen Y, et al: Etiology of choroidal neovascularization in young patients.  Ophthalmology  1996; 103:1241-1244.

29. Yoshida T, Ohno-Matsui K, Ohtake Y, et al: Myopic choroidal neovascularization: a 10-year follow-up.  Ophthalmology  2003; 110:1297-1305.

30. Hayashi K, Ohno-Matsui K, Yoshida T, et al: Characteristics of patients with a favorable natural course of myopic choroidal neovascularization.  Graefe's Arch Clin Exp Ophthalmol  2005; 243:13-19.

31. Kojima A, Ohno-Matsui K, Teramukai S, et al: Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia.  Graefe's Arch Clin Exp Ophthalmol  2004; 242:114-119.

32. Jalkh AE, Weiter JJ, Trempe CL, et al: Choroidal neovascularization in degenerative myopia: role of laser photocoagulation.  Ophthalmic Surg  1987; 18:721-725.

33. Soubrane G, Pison J, Bornert P, et al: Neovaisseaux sous-retiniens de la myopie degerative: resultants de la photocoagulation.  Bull Soc Ophthalmol Fr  1986; 86:269-272.

34. Brancato R, Menchini U, Pece A, et al: Dye laser photocoagulation of macular subretinal neovascularization in pathological myopia. A randomized study of three different wavelengths.  Int Ophthalmol  1997; 7:339-344.

35. Pece A, Brancato R, Avanza P, et al: Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results.  Int Ophthalmol  1994; 18:339-344.

36. Secretan M, Kuhn D, Soubrane G, et al: Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment.  Eur J Opthalmol  1997; 7:307-316.

37. Vertepor-n in Photodynamic Therapy (VIP) Study Group : Vertepor-n therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3.  Ophthalmology  2003; 110:667-673.

38. Schnurrbusch UE, Jochmann C, Wiedemann P, et al: Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia.  Graefe's Arch Clin Exp Ophthalmol  2005; 243:829-833.

39. Potter MJ, Szabo SM, Ho T: Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year-old girl.  Graefe's Arch Clin Exp Ophthalmol  2005; 21:1-3.

40. Adamis AP, Miller JW, Bernal MT, et al: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.  Am J Ophthalmol  1994; 118:445-450.

41. Aiello LP, Avery RL, Arrigg PG, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  N Engl J Med  1994; 331:1480-1487.

42. Nguyen QD, Shah S, Tatlipinar S, et al: Bevacizumab suppresses choroidal neovascularization caused by pathologic myopia.  Br J Ophthalmol  2005; 89:1368-1370.

43. Ruiz-Moreno JM, de la Vega C: Surgical removal of subfoveal choroidal neovascularization in highly myopic patients.  Br J Ophthalmol  2001; 85:1041-1043.

44. Uemura A, Thomas MA: Subretinal surgery for choroidal neovascularization in patients with high myopia.  Arch Ophthalmol  2000; 118:344-350.

45. Haemlin N, Glacet-Bernard A, Brindeau C, et al: Surgical treatment of subfoveal neovascularization in myopia: macular translocation versus surgical removal.  Am J Ophthalmol  2002; 133:530-536.

46. Machemer R, Steinhorst UH: Retinal separation, retinotomy, and macular relocation. II. A surgical approach for macular degeneration.  Ophthalmology  1999; 101:1384-1396.

47. Bedrossian RH: The effect of atropine on myopia.  Ophthalmology  1999; 86:713-719.

48. Shih YF, Hsiao CK, Chen CJ, et al: An intervention trial on ef-cacy of atropine and multi-focal glasses in controlling myopic progression.  Acta Ophthalmol Scand  1999; 79:233-236.

49. Siatkowski RM, Cotter S, Miller JM, et al: US pirenzapine study group. Safety and ef-cacy of 2% pirenzapine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study.  Arch Ophthalmol  2004; 122:1667-1674.

50. Coroneo MT, Beaumont JT, Hollows FC: Scleral reinforcement in the treatment of pathologic myopia.  Aust N Z J Ophthalmol  1998; 16:317-320.

51. Gregg FM, Feinberg EB: X-linked pathologic myopia.  Ann Ophthalmol  1992; 24:310-312.

52. Paluru PC, Nallasamy S, Devoto D, et al: Identi-cation of a novel locus on 2q for autosomal dominant high-grade myopia.  IOVS  2005; 46:2300-2307.